Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical Pharmacokinetics
Erschienen in: Clinical Pharmacokinetics 3/2018

21.06.2017 | Original Research Article

Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial

verfasst von: Rong Deng, Ai Ping Lee, Mauricio Maia, Jeremy J. Lim, Tracy Burgess, Priscilla Horn, Michael A. Derby, Elizabeth Newton, Jorge A. Tavel, William D. Hanley

Erschienen in: Clinical Pharmacokinetics | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Background and Objectives

MHAA4549A, a human anti-influenza immunoglobulin (Ig) G1 monoclonal antibody, is being developed to treat patients hospitalized for influenza A infection. This study examined the pharmacokinetics (PKs) of MHAA4549A in a phase IIa, randomized, double-blind, dose-ranging trial in healthy volunteers challenged with influenza A virus.

Methods

Serum PK data were collected from 60 subjects in three single-dose groups (400, 1200, or 3600 mg) who received MHAA4549A intravenously 24–36 h after inoculation with the influenza A virus. Nasopharyngeal swab MHAA4549A concentration data were collected on days 1–8, and all subjects, including the placebo group, received 75 mg oseltamivir twice daily from days 7 to 11. Plasma samples were collected 4 h postdose on day 8 for oseltamivir and its active metabolite oseltamivir carboxylate (OC) (all subjects, n = 100), including subjects treated with oseltamivir alone and placebo. Noncompartmental analysis was performed for both nasal and serum PKs.

Results

MHAA4549A showed dose-proportional serum PKs with a long terminal half-life (approximately 21.9–24.6 days) and slow clearance (approximately 152–240 mL/day); however, nasopharyngeal swab PKs were not dose proportional. No differences in mean plasma concentrations of oseltamivir and OC at 4 h postdose on day 8 were observed between the MHAA4549A treatment and placebo groups. No subjects who received MHAA4549A developed anti-drug antibodies.

Conclusion

MHAA4549A serum PKs were consistent with that of a human IgG1antibody without known endogenous targets. MHAA4549A showed nonlinear PKs in nasopharyngeal swab samples, which will guide future dose selection to achieve the high drug concentrations needed at the site of action for efficacy. These data demonstrate no PK interactions between MHAA4549A and oseltamivir, and support flat dosing.

Trial Registration

ClinicalTrials.gov identifier, NCT01980966.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Matias G, Taylor R, Haguinet F, Schuck-Paim C, Lustig R, Shinde V. Estimates of mortality attributable to influenza and RSV in the United States during 1997-2009 by influenza type or subtype, age, cause of death, and risk status. Influ Other Respir Viruses. 2014;8:507–15.CrossRef
3.
Snacken R, Quinten C, Devaux I, Plata F, Broberg E, Zucs P, et al. Surveillance of hospitalised severe cases of influenza A(H1N1)pdm09 and related fatalities in nine EU countries in 2010-2011. Influ Other Respir Viruses. 2012;6:e93–6.CrossRef
4.
Finkelman BS, Viboud C, Koelle K, Ferrari MJ, Bharti N, Grenfell BT. Global patterns in seasonal activity of influenza A/H3N2, A/H1N1, and B from 1997 to 2005: viral coexistence and latitudinal gradients. PLoS One. 2007;2:e1296.CrossRefPubMedPubMedCentral
5.
Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36–44.CrossRefPubMed
6.
Wang Z, Tobler S, Roayaei J, Eick A. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA. 2009;301(9):945–53.CrossRefPubMed
7.
Tisa V, Barberis I, Faccio V, Paganino C, Trucchi C, Martini M, et al. Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden. J Prev Med Hyg. 2016;57:E28–33.PubMedPubMedCentral
8.
Grohskopf LA, Sokolow LZ, Broder KR, Olsen SJ, Karron RA, Jernigan DB, et al. Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep. 2016;65:1–54.CrossRefPubMed
9.
Neu KE, Henry Dunand CJ, Wilson PC. Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease? Curr Opin Immunol. 2016;42:48–55.CrossRefPubMedPubMedCentral
10.
11.
Nachbagauer R, Krammer F. Universal influenza virus vaccines and therapeutic antibodies. Clin Microbiol Infect. 2017;23(4):222–8.CrossRefPubMed
12.
de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol. 2000;61:94–9.CrossRefPubMed
13.
Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11:153.CrossRefPubMedPubMedCentral
14.
Kandel R, Hartshorn KL. Prophylaxis and treatment of influenza virus infection. BioDrugs. 2001;15:303–23.CrossRefPubMed
15.
Kohno S, Kida H, Mizuguchi M. Shimada J; S-021812 Clinical Study Group. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54:4568–74.CrossRefPubMedPubMedCentral
16.
Monto AS, Moult AB, Sharp SJ. Effect of zanamivir on duration and resolution of influenza symptoms. Clin Ther. 2000;22:1294–305.CrossRefPubMed
17.
Monto AS, Fleming DM, Henry D, de Groot R, Makela M, Klein T, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis. 1999;180:254–61.CrossRefPubMed
18.
Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase inhibitor flu treatment investigator group. Lancet. 2000;355:1845–50.CrossRefPubMed
19.
Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, Wat C, IMPACT Study Group, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother. 2003;51:123–9.CrossRefPubMed
20.
Nakamura G, Chai N, Park S, Chiang N, Lin Z, Chiu H, et al. An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe. 2013;14:93–103.CrossRefPubMed
21.
Kamen L, Kho E, Lin YL, Chung S. Anti-influenza antibody MHAA4549A induces ADCC in influenza-infected cells. Presented at the Keystone Symposium on Molecular and Cellular Biology: Antibodies as Drugs (X2). Whistler; 2016 (6–10 March 2016).
22.
Lim JJ, Deng R, Derby MA, Larouche R, Horn P, Anderson M, et al. Two phase 1, randomized, double-blind, placebo-controlled, single ascending-dose studies to investigate the safety, tolerability, and pharmacokinetics of an anti-influenza a monoclonal antibody, MHAA4549A, in healthy volunteers. Antimicrob Agents Chemother. 2016;60:5437–44.CrossRefPubMedPubMedCentral
23.
McBride JM, Rosenberger C, Tavel JA, Deng R, Derby MA, Burgess T, et al. Clinical safety and efficacy of MHAA4549A, a novel monoclonal antibodyfor the treatment of severe influenza a: results of a randomized, double-blind, placebo controlled clinical trial [poster No. 20161]. Presented at the Keystone Symposium on Molecular and Cellular Biology: Viral Immunity. Breckenridge; 2015 (11–16 Jan 2015).
24.
Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282:1240–6.CrossRefPubMed
25.
Rayner CR, Chanu P, Gieschke R, Boak LM, Jonsson EN. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J Clin Pharmacol. 2008;48:935–47.CrossRefPubMed
26.
Kamal MA, Van Wart SA, Rayner CR, Subramoney V, Reynolds DK, Bulik CC, et al. Population pharmacokinetics of oseltamivir: pediatrics through geriatrics. Antimicrob Agents Chemother. 2013;57:3470–7.CrossRefPubMedPubMedCentral
27.
Monto AS, Ceglarek JP, Hayner NS. Liver function abnormalities in the course of a type A (H1N1) influenza outbreak: relation to Reye’s syndrome. Am J Epidemiol. 1981;114:750–9.CrossRefPubMed
28.
Polakos NK, Cornejo JC, Murray DA, Wright KO, Treanor JJ, Crispe IN, et al. Kupffer cell-dependent hepatitis occurs during influenza infection. Am J Pathol. 2006;168:1169–78.CrossRefPubMedPubMedCentral
29.
Yingying C. Abnormal liver chemistry in patients with influenza A H1N1. Liver Int. 2011;31:902.CrossRefPubMed
30.
Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633–59.CrossRefPubMed
31.
Gupta P, Kamath AV, Park S, Chiu H, Lutman J, Maia M, et al. Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A. MAbs. 2016;8:991–7.CrossRefPubMedPubMedCentral
32.
Darouiche R, Perkins B, Musher D, Hamill R, Tsai S. Levels of rifampin and ciprofloxacin in nasal secretions: correlation with MIC90 and eradication of nasopharyngeal carriage of bacteria. J Infect Dis. 1990;162:1124–7.CrossRefPubMed
33.
Shelton MJ, Lovern M, Ng-Cashin J, Jones L, Gould E, Gauvin J, et al. Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects. Antimicrob Agents Chemother. 2011;55:5178–84.CrossRefPubMedPubMedCentral
34.
Wollacott AM, Boni MF, Szretter KJ, Sloan SE, Yousofshahi M, Viswanathan K, et al. Safety and upper respiratory pharmacokinetics of the hemagglutinin stalk-binding antibody VIS410 support treatment and prophylaxis based on population modeling of seasonal influenza A outbreaks. EBioMedicine. 2016;5:147–55.CrossRefPubMedPubMedCentral
35.
Adawi A, Bisignano C, Genovese T, Filocamo A, Khouri-Assi C, Neville A, et al. In vitro and in vivo properties of a fully human IgG1 monoclonal antibody that combats multidrug resistant Pseudomonas aeruginosa. Int J Mol Med. 2012;30:455–64.CrossRefPubMedPubMedCentral
36.
37.
38.
Lee N, Ison MG. Diagnosis, management and outcomes of adults hospitalized with influenza. Antiviral Ther. 2012;17:143–57.CrossRef
39.
Deng R, Jin F, Prabhu S, Iyer S. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol. 2012;8:141–60.CrossRefPubMed
40.
Olofsson SK, Cars O. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis. 2007;45(suppl 2):S129–36.CrossRefPubMed
41.
Chai N, Swem LR, Reichelt M, Chen-Harris H, Luis E, Park S, et al. Two escape mechanisms of influenza A virus to a broadly neutralizing stalk-binding antibody. PLoS Pathog. 2016;12:e1005702.CrossRefPubMedPubMedCentral
42.
Girish S, Martin SW, Peterson MC, Zhang LK, Zhao H, Balthasar J, et al. AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical development. AAPS J. 2011;13:405–16.CrossRefPubMedPubMedCentral
43.
44.
Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer LA, et al. A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet. 2012;51:119–35.CrossRefPubMed
45.
Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009;49:1012–24.CrossRefPubMed
46.
Zhang S, Shi R, Li C, Parivar K, Wang DD. Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults. J Clin Pharmacol. 2012;52:18–28.CrossRefPubMed
47.
Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645–68.CrossRefPubMed
48.
Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother. 2010;65(suppl 2):ii5–10.PubMedPubMedCentral
49.
He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 1999;37:471–84.CrossRefPubMed
Metadaten
Titel
Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial
verfasst von
Rong Deng
Ai Ping Lee
Mauricio Maia
Jeremy J. Lim
Tracy Burgess
Priscilla Horn
Michael A. Derby
Elizabeth Newton
Jorge A. Tavel
William D. Hanley
Publikationsdatum
21.06.2017
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 3/2018
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-017-0564-y

Weitere Artikel der Ausgabe 3/2018

Clinical Pharmacokinetics 3/2018 Zur Ausgabe

Review Article

The Clinical Pharmacology of Elotuzumab

Original Research Article

A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients

Original Research Article

Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease

Original Research Article

Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine

Review Article

Pharmacokinetics and Pharmacodynamics of Temocillin

Original Research Article

Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer